ArticleCureus2026
Prognostic Value of Plasma N-terminal Pro-B-Type Natriuretic Peptide (Nt-proBNP) Levels in Patients Presenting With Cardiac Arrhythmias to the Emergency Department: A Prospective Observational Study From India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and rationaleN-terminal pro-B-type natriuretic peptide (NT-proBNP), a key marker of cardiac stress, is widely used in heart failure care. However, its role in patients presenting to the Emergency Department (ED) with cardiac arrhythmias remains underexplored. AIMS AND
objectivesTo evaluate the prognostic significance of plasma NT-proBNP levels in patients presenting to the ED with cardiac arrhythmias and to assess their clinical profile. METHODOLOGY: A prospective observational study was conducted over 18 months, from September 2023 to December 2024, with data analysis performed from January 2025 to May 2025, in the Department of Trauma and Emergency, All India Institute of Medical Sciences (AIIMS) Jodhpur, India. Patients aged ≥18 years with various arrhythmias were enrolled, excluding those with pre-existing heart failure, renal dysfunction, or structural heart disease. NT-proBNP levels, echocardiographic findings, clinical symptoms, and laboratory parameters were recorded and correlated with immediate outcomes (rhythm reversion versus recurrence). Arrhythmia recurrence was defined as the recurrence of the same or another clinically significant arrhythmia during hospitalization or within a seven-day follow-up period.
resultsIn 194 patients with cardiac arrhythmias, 35.6% achieved rhythm reversion, while 64.4% experienced recurrence. NT-proBNP levels were significantly higher in the recurrence group (8545.53 vs. 2555.06 pg/mL, p=0.001), consistent across all left ventricular ejection fraction (LVEF) categories. Elevated NT-proBNP, sepsis, high-sensitivity C-reactive protein (hs-CRP), and low hemoglobin predicted poorer outcomes in univariable analyses, with septic shock showing the strongest adverse prognostic impact (p=0.015).
conclusionElevated NT-proBNP levels were associated with an increased risk of arrhythmia recurrence and adverse short-term outcomes in patients presenting with cardiac arrhythmias. These associations were observed across different LVEF categories, suggesting that NT-proBNP may reflect underlying cardiac stress and overall illness severity. Sepsis and inflammatory states were also associated with poorer outcomes, highlighting the multifactorial nature of risk in this population. NT-proBNP may have utility as a risk stratification marker in the ED; however, larger prospective studies with multivariable adjustment are required to validate these findings and determine its independent prognostic value.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.